JHC
SLN

Jones Hill Capital’s Silence Therapeutics SLN Stock Holding History

Jones Hill Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-301,604
Closed -$1.59M – 35
2026
Q1 		$1.59M Buy
+301,604
New +$1.66M 0.34% 25

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Jones Hill Capital's SLN Position: Q2 2026 in Review

Jones Hill Capital sold out of Silence Therapeutics (SLN) in Q2 2026, closing a stake of 301,604 shares — an estimated $1.59M sold.

Jones Hill Capital first reported a position in SLN in Q1 2026 and held it in 1 quarter. The position peaked at $1.59M in Q1 2026. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Jones Hill Capital reported no remaining Silence Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jones Hill Capital sold 301,604 Silence Therapeutics shares in Q2 2026, an estimated $1.59M.
  • Jones Hill Capital first reported a position in Silence Therapeutics in Q1 2026 and held it in 1 quarter.
  • Jones Hill Capital's Silence Therapeutics position peaked at $1.59M in Q1 2026.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.